Combination vaccine

Patent metadata

Field	Value
Publication number	US-11266735-B2
Application number	US-202016781781-A
Country	US
Kind code	B2
Filing date	Feb 4, 2020
Priority date	Aug 21, 2013
Publication date	Mar 8, 2022
Grant date	Mar 8, 2022

Abstract

The present invention relates to a vaccine, especially a combination vaccine providing at least a first and a second antigenic function, the combination vaccine comprising at least one RNA encoding at least one or more proteins or fragments, variants or derivatives of proteins awarding antigenic function, wherein the first antigenic function being a Fusion (F) protein or a fragment, variant or derivative of a Fusion (F) protein derived from the virus family Paramyxoviridae and the second antigenic function being an Hemagglutinin (HA) protein or a fragment, variant or derivative of an Hemagglutinin (HA) protein derived from the virus family Orthomyxoviridae. Furthermore, the present invention is directed to a kit or kit of parts comprising the components of said combination vaccine and to said combination vaccine for use in a method of prophylactic or therapeutic treatment of diseases, particularly in the prevention or treatment of infectious diseases like RSV and influenza.

First claim

The invention claimed is:

1. A composition comprising an mRNA encoding an extracellular domain of a Fusion (F) protein from a virus of the family Paramyxoviridae, and an mRNA encoding an extracellular domain of a Hemagglutinin (HA) protein from a virus of the family Orthomyxoviridae.

2. The composition of claim 1 , comprising a first monocistronic mRNA that encodes the extracellular domain of the Fusion (F) protein and a second monocistronic mRNA that encodes the extracellular domain of the Hemagglutinin (HA) protein.

3. The composition of claim 1 , comprising a bicistronic or a multicistronic mRNA wherein at least one open reading frame encodes the extracellular domain of the Fusion (F) protein and wherein at least another open reading frame encodes the extracellular domain of the Hemagglutinin (HA) protein.

4. The composition of claim 1 , wherein the extracellular domain of the Fusion (F) protein is from viruses selected from: Avulavirus, Ferlavirus, Henipavirus, Morbillivirus, Respirovirus, Rubulavirus, TPMV-like viruses, Pneumovirus, Metapneumovirus, Atlantic salmon paramyxovirus, Beilong virus, J virus, Mossman virus, Nariva virus, Salem virus, or Pacific salmon paramyxovirus.

5. The composition of claim 1 , wherein the extracellular domain of the Fusion (F) protein is from human respiratory syncytial virus (RSV).

6. The composition of claim 5 , wherein the extracellular domain of the Fusion (F) protein is from human respiratory syncytial virus (RSV), selected from RSV Long or RSV A2, and wherein the Fusion (F) protein is a protein encoded by one of the sequences according to SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 19, or SEQ ID NO: 20.

7. The composition of claim 5 , wherein the extracellular domain of the Hemagglutinin (HA) protein is from an Influenza virus.

8. The composition of claim 7 , wherein the mRNA is a stabilized RNA by modification of the G/C-content.

9. A kit comprising: (1) a mRNA encoding an extracellular domain of the Fusion (F) protein from a virus of the family Paramyxoviridae; and (2) a mRNA encoding an extracellular domain of the Hemagglutinin (HA) protein from a virus of the family Orthomyxoviridae.

10. The composition of claim 5 , wherein the extracellular domain of the F protein is from RSV Long or RSV A2 virus.

11. The composition of claim 10 , wherein the extracellular domain of the F protein is selected from a protein according to one of the sequences according to SEQ ID NO: 1 or SEQ ID NO: 2.

12. The composition of claim 7 , wherein the extracellular domain of the HA protein is from an Influenza A, Influenza B, Influenza C, Isavirus, Thogotovirus, Quaranfil virus, Johnston Atoll virus, or Lake Chad virus.

13. The composition of claim 12 , wherein the extracellular domain of the HA protein is from Influenza A virus.

14. The composition of claim 12 , wherein the extracellular domain of the HA protein comprises a sequence according to SEQ ID NO: 3.

15. The composition of claim 8 , wherein the extracellular domain of the HA protein is from an Influenza A virus and wherein the extracellular domain of the F protein is from a RSV.

16. The composition of claim 1 , further comprising an adjuvant component.

17. The composition of claim 15 , comprising a first monocistronic mRNA that encodes the extracellular domain of the Fusion (F) protein and a second monocistronic mRNA that encodes the extracellular domain of the Hemagglutinin (HA) protein.

Assignees

• Curevac Ag

Inventors

• Kallen Karl-Josef
• Kramps Thomas
• Schnee Margit
• Voss Daniel

Classifications

• A61K39/12

  Viral antigens · CPC title

• A61K2039/572

  cytotoxic response · CPC title

• A61K39/145

  Orthomyxoviridae, e.g. influenza virus · CPC title

• A61K39/155 Primary

  Paramyxoviridae, e.g. parainfluenza virus · CPC title

• C12N2760/18534

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title